Lab result explainedInflammationLast updated November 11, 2026

Anti-dsDNA antibody test: normal range, what a high or positive result means and its link to lupus

Anti-double-stranded DNA antibody (Anti-dsDNA) · Lupus serology (ordered after a positive ANA, usually with complement C3 and C4 and an ENA panel) · reported in IU/mL on ELISA and chemiluminescent assays (cut-offs differ by kit); a titer such as 1:10 on the Crithidia luciliae immunofluorescence test; some labs report an index

Anti-double-stranded DNA (anti-dsDNA) antibodies are autoantibodies against the DNA in cell nuclei, and the anti-dsDNA test is the most specific common blood test for systemic lupus erythematosus (SLE). A normal result is negative. On the ELISA and chemiluminescent assays most US labs use, that means below the kit's cut-off, often under 30 IU/mL, with values up to about 75 IU/mL called borderline and higher values positive, although cut-offs differ widely between kits. A clearly positive result in someone with a positive ANA and symptoms such as joint pain, rash, mouth ulcers, pleurisy or protein in the urine strongly supports lupus.

The test is specific but not sensitive. A positive result is found in 5 percent or fewer of people without lupus (specificity of roughly 95 to 97 percent on the better assays), but only 50 to 70 percent of people with lupus are positive at diagnosis and around 30 percent are never positive, so a negative result does not rule lupus out. Low-level positives occur in other autoimmune diseases, during infections and with certain drugs, and the ELISA format produces more of these than the older Crithidia luciliae immunofluorescence test, which is why a borderline ELISA is often confirmed by a second method.

Unlike the ANA, which stays positive at a similar level for years, anti-dsDNA rises and falls with lupus activity in many people, particularly those with kidney involvement. A rising titer together with falling complement C3 and C4 often precedes a flare by weeks to months, and the combination is one of the main ways clinicians track the disease. Because the correlation is imperfect (some people run high titers while well), treatment decisions are made on symptoms and organ tests, with the antibody as supporting evidence rather than a target.

Anti-dsDNA at a glance

What it is: an autoantibody against double-stranded DNA; the most lupus-specific routine antibody test, usually ordered after a positive ANA.
Normal: negative, below the assay cut-off (often under 30 IU/mL on ELISA; some kits use 10, 100 or 200 IU/mL, so read the printed range). Crithidia test: negative below 1:10.
Positive: above the cut-off; borderline results (for example 30–75 IU/mL) are repeated or confirmed by Crithidia immunofluorescence before conclusions are drawn.
Specificity for lupus is about 95 percent, but only 50–70 percent of people with lupus are positive, so a negative result does not exclude it.
High and rising titers with low C3 and C4 point to active disease, especially lupus nephritis; the test is repeated every 3 to 6 months in known lupus.
Low positives also occur in autoimmune hepatitis, Sjögren's syndrome, infections, on TNF-inhibitor drugs and in 1–3 percent of healthy people.

Have your whole report? Paste it into the free Lab Explainer

Every marker explained in plain language, in context with the others, with questions to bring to your appointment. No account needed.

What Anti-dsDNA measures

DNA from dying cells is normally cleared quietly. In lupus, impaired clearance of nuclear debris and over-active type I interferon signaling present DNA and the proteins wrapped around it to the immune system, which responds with IgG antibodies against the double helix itself. These antibodies form immune complexes with circulating DNA and nucleosomes that deposit in the kidney's filtering units and in skin and blood vessels, activating complement and causing inflammation; some bind directly to kidney tissue. This is why anti-dsDNA is tied to lupus nephritis more than to any other feature, and why complement falls as it rises.

Three methods are in use. The Farr radioimmunoassay, now rare, detects high-avidity antibodies and is the most disease-specific. The Crithidia luciliae indirect immunofluorescence test (CLIFT) uses a parasite with a kinetoplast of pure double-stranded DNA; a positive is a titer of 1:10 or above and is very specific. Enzyme immunoassays (ELISA) and the chemiluminescent and multiplex platforms that have largely replaced them are automated and sensitive but detect lower-avidity antibodies as well, so they generate more low positives in people without lupus. Results are in IU/mL calibrated against a WHO reference, but because kits differ in what they capture, a value of 40 on one may be 150 on another; only the printed cut-off applies.

The 2019 EULAR/ACR classification criteria award 6 points (the same as anti-Smith) to anti-dsDNA only when it is measured by an assay with at least 90 percent specificity against relevant disease controls, which in practice means a Farr, Crithidia or well-validated high-cut-off ELISA result. Antibodies may appear years before symptoms: in a US military cohort, anti-dsDNA was detectable a mean of 2.2 years before lupus was diagnosed.

Normal range for Anti-dsDNA

Reference ranges vary between labs and by age, sex and pregnancy. Use the range printed on your own report.

Group	Typical range (IU/mL on ELISA and chemiluminescent assays (cut-offs differ by kit); a titer such as 1:10 on the Crithidia luciliae immunofluorescence test; some labs report an index)	Notes
Negative	Below the assay cut-off (for many ELISAs under 30 IU/mL; others use 10, 100 or 200 IU/mL)	Labs differ widely; use the printed range. A negative result does not exclude lupus.
Borderline or equivocal	Just above the cut-off (for example 30–75 IU/mL on a 30 IU/mL kit)	Seen in healthy people, other autoimmune diseases and infections. Usually repeated in 6 to 12 weeks or confirmed by Crithidia immunofluorescence.
Positive	Above the equivocal band (for example above 75 IU/mL)	Supports lupus in the right clinical setting; interpret with the ANA, complement, urine tests and symptoms.
High positive	Several times the cut-off (often above 200–300 IU/mL)	More likely to indicate active disease and kidney involvement; a doubling of titer with falling C3 and C4 is a flare signal.
Crithidia luciliae (CLIFT), negative	Below 1:10	Highly specific; a negative Crithidia with a low-positive ELISA usually means the ELISA was a false positive.
Crithidia luciliae, positive	1:10 and above, in doubling titers (1:10, 1:20, 1:40, up to 1:1280 or more)	Higher titers track more closely with nephritis and disease activity.
Farr assay	Positive above about 7 IU/mL (kit-dependent)	Detects high-avidity antibodies; now mostly used in research and a few reference labs.
Monitoring in known lupus	The trend over time matters more than one value	Many clinicians retest every 3 to 6 months; a rise of 50 to 100 percent with falling complement predicts a flare in a proportion of patients.

Positive or high anti-dsDNA

A clearly positive anti-dsDNA in someone with a positive ANA and compatible symptoms is strong evidence of systemic lupus erythematosus; few other conditions produce it, and the higher the titer and the more specific the assay, the more confident the interpretation. It also says something about the type of lupus: anti-dsDNA-positive patients have more kidney disease, lower complement and more blood-count abnormalities than those who are negative.

A low positive, especially on an ELISA with a negative Crithidia test, a negative ANA or no symptoms, is a different message. Between 1 and 3 percent of healthy people have low-level anti-dsDNA on automated assays, as do some people with autoimmune hepatitis, Sjögren's syndrome, rheumatoid arthritis and chronic infections, and some of those on TNF-inhibitor biologics. These low positives rarely progress to lupus and are followed rather than treated.

In established lupus the number is a barometer rather than a verdict. In roughly half of patients the titer tracks disease activity, rising before flares of nephritis and falling with treatment, and in these people a sharp rise with falling C3 and C4 prompts closer monitoring and sometimes earlier adjustment of therapy. In the other half the antibody stays high during remission or never rises in a flare, so decisions rest on symptoms, urine tests, blood counts and kidney function, with the antibody as one input.

Common causes

Systemic lupus erythematosus
By far the most common cause of a clearly positive result; present in 50 to 70 percent of patients at some point and in up to 90 percent of those with active nephritis. Titers are typically highest in untreated, active disease.
Lupus nephritis
Immune complexes containing anti-dsDNA deposit in the glomeruli. A high or rising titer with low complement, protein or blood in the urine or a rising creatinine points to kidney involvement, which needs prompt evaluation and often a kidney biopsy.
Drug-induced antibodies
TNF inhibitors (infliximab, adalimumab, etanercept) induce anti-dsDNA in roughly 10 to 15 percent of users, usually low titer and without lupus symptoms. Procainamide, hydralazine, minocycline and isoniazid more often cause anti-histone antibodies with a positive ANA; anti-dsDNA is uncommon in classic drug-induced lupus.
Autoimmune hepatitis and other autoimmune diseases
Anti-dsDNA is reported in a proportion of people with type 1 autoimmune hepatitis, Sjögren's syndrome, mixed connective tissue disease and rheumatoid arthritis, usually at low titer and on ELISA rather than Crithidia.
Infections
Epstein-Barr virus, HIV, hepatitis B and C, parvovirus B19, endocarditis, tuberculosis and other chronic infections can produce transient low-positive results through broad immune activation; they clear as the infection resolves.
Healthy people and relatives of lupus patients
Automated assays find low-level anti-dsDNA in 1 to 3 percent of healthy adults and more often in first-degree relatives of people with lupus; most never develop disease, although the antibody can precede lupus by years.
Assay-related false positives
ELISA plates can pick up antibodies to single-stranded or denatured DNA, and rheumatoid factor or very high immunoglobulin levels occasionally interfere. A positive ELISA with a negative Crithidia and a negative ANA is usually a technical false positive.
Cancer and other rare causes
Lymphoma and some other malignancies, chronic active hepatitis and, rarely, primary biliary cholangitis have been associated with low-level anti-dsDNA; these are uncommon explanations found by the wider work-up rather than by this test.

Symptoms that can go with it

Joint pain and swelling, typically symmetrical in the hands, wrists and knees, worse in the morning
A rash across the cheeks and nose or other rashes that flare after sun exposure
Mouth or nose ulcers, often painless, and patchy hair loss
Fatigue, low-grade fever, weight loss and swollen glands
Chest pain that is worse on breathing in (pleurisy or pericarditis)
Foamy urine, swelling of the ankles or around the eyes, or rising blood pressure (kidney involvement)
Fingers turning white then blue in the cold (Raynaud's phenomenon)
Easy bruising, frequent infections or pallor from low blood counts; headaches, confusion or seizures in neurological lupus

Read it alongside

ANA — the screening test; anti-dsDNA is nearly always accompanied by a positive ANA (usually a homogeneous pattern), and dsDNA positivity with a negative ANA is suspect.
Complement C3 and C4 — low complement with high anti-dsDNA is the serological signature of active lupus and particularly nephritis.
ENA panel (anti-Smith, RNP, SSA/Ro, SSB/La) — anti-Smith is equally specific for lupus and the others shape the picture; ordered together after a positive ANA.
Urine albumin-to-creatinine ratio and urinalysis with microscopy — protein, blood or cellular casts in the urine with a high anti-dsDNA are the signal to look for lupus nephritis.
Creatinine and eGFR — kidney function is checked at every visit in anti-dsDNA-positive lupus.
CBC with differential — low white cells, lymphocytes, platelets or hemoglobin (sometimes with a positive Coombs test) are common in active lupus and are part of the classification criteria.
ESR and CRP — the ESR rises with lupus activity while CRP often stays low; a high CRP in lupus suggests infection or serositis rather than a flare.
Antiphospholipid antibodies and lupus anticoagulant — checked in everyone with lupus because they change clot and pregnancy risk.

What usually happens next

A new positive is interpreted with your symptoms, an ANA with pattern and titer, complement C3 and C4, a CBC, creatinine and a urinalysis with albumin-to-creatinine ratio; expect a rheumatology referral if any of these is abnormal or you have lupus symptoms.
A borderline or isolated ELISA positive with no symptoms is usually repeated in 6 to 12 weeks or confirmed with a Crithidia luciliae test rather than acted on.
If you already have lupus, the result is compared with your own previous values; a rise with falling complement prompts a closer look at urine, blood pressure and kidney function and a sooner follow-up visit.
Ask which assay your lab uses and what its cut-off is, since 'positive' means different numbers on different platforms, and ask that the same lab is used for monitoring.
If you are planning pregnancy, raise it: active lupus with high anti-dsDNA and low complement in the months before conception raises the risk of flare and preeclampsia, and the aim is about 6 months of quiet disease first.

Diet, lifestyle and natural levers with evidence

What can move Anti-dsDNA once the cause is known. Nothing here replaces finding the cause.

Nothing natural turns a positive anti-dsDNA negative

Strong evidence

No diet, herb or supplement has been shown to make anti-dsDNA disappear, and titers fluctuate on their own with disease activity, so changes after starting a product prove nothing. Immunosuppressive treatment of active lupus lowers the titer; the levers below have modest effects on disease activity in trials, and a few on the antibody level itself.

Vitamin D repletion if you are deficient

Moderate evidence

Low vitamin D is common in lupus because of sun avoidance and steroids. In a randomized placebo-controlled trial of 267 patients, 2,000 IU of vitamin D a day for 12 months lowered disease activity scores and anti-dsDNA levels modestly and raised complement compared with placebo. Smaller trials have been mixed, and there is no evidence that vitamin D prevents lupus in antibody-positive people without disease.

Check a 25-hydroxyvitamin D level and avoid high doses if you have kidney disease, kidney stones, high calcium or sarcoidosis.

Stopping smoking

Moderate evidence

In a case-control study of lupus patients, current smokers were about four times as likely as never-smokers to be anti-dsDNA positive, and smoking is associated with higher disease activity, more skin disease and a poorer response to hydroxychloroquine, the cornerstone lupus drug. Ex-smokers resemble never-smokers in these studies, so quitting is one of the few lifestyle changes with a plausible effect on the antibody itself.

Sun protection

Moderate evidence

Ultraviolet light kills skin cells and releases nuclear material, which in lupus feeds the antibody response and triggers skin and systemic flares. In controlled studies, broad-spectrum SPF 50 sunscreen prevented UV-induced skin lesions in people with lupus, and daily sun protection is a standard EULAR recommendation. It reduces flares rather than lowering a titer directly.

Omega-3 fatty acids

Preliminary evidence

Two small randomized trials in lupus (about 50 patients each, 3 g a day of EPA plus DHA for 6 months) found modest improvements in disease activity scores or fatigue compared with placebo, with no consistent change in anti-dsDNA. The effect is small and the evidence thin; omega-3 is not a substitute for prescribed treatment.

Doses above 3 g a day increase bleeding tendency, which matters if you also take aspirin or anticoagulants for antiphospholipid antibodies.

When to see a clinician promptly

Foamy urine, visible blood in the urine, swelling of the ankles, legs or around the eyes, or a new rise in blood pressure: possible lupus nephritis, which needs urgent kidney assessment (a creatinine rising over days to weeks is an emergency).
Chest pain that is worse on breathing in or lying flat, or breathlessness, which can be pleurisy, pericarditis or a clot.
Fever above 100.4°F (38°C) if you take steroids or immunosuppressants, when infection must be excluded quickly.
New confusion, seizures, severe headache, weakness on one side or sudden vision change.
Unexplained bruising, bleeding gums, very pale skin with breathlessness, or a platelet count under 50,000 per microliter on a blood test.
A rising anti-dsDNA with falling C3 and C4 on routine monitoring, even if you feel well, so that your care plan can be reviewed before a flare.

Frequently asked questions

What is a normal anti-dsDNA level?

Negative, which means below your lab's cut-off. On many ELISA kits that is under 30 IU/mL, with 30 to 75 borderline and above 75 positive, but other kits set the line at 10, 100 or 200 IU/mL and some labs report an index with negative below 1.0. On the Crithidia luciliae test, negative is below 1:10. Because the number means different things on different platforms, compare only with the range printed on your own report.

Is an anti-dsDNA of 30, 50 or 100 IU/mL high?

It depends on the kit. On a 30 IU/mL assay, 30 to 75 is borderline and 100 is positive; on a 100 or 200 IU/mL assay, all three are negative. A borderline value with a negative ANA and no symptoms is most often a false positive and is repeated or confirmed by Crithidia; the same value in someone with a positive ANA, low complement and joint pain is meaningful. The trend over time and the company it keeps matter more than the single number.

Can you have a positive anti-dsDNA and not have lupus?

Yes, mainly at low titer on ELISA-type assays. Low positives occur in 1 to 3 percent of healthy people, in autoimmune hepatitis, Sjögren's syndrome and rheumatoid arthritis, during infections such as EBV and hepatitis C, and in 10 to 15 percent of people taking TNF inhibitors, usually without lupus symptoms. A high titer, or a positive Crithidia test, is rarely anything but lupus. Antibodies can also appear years before lupus declares itself, so an unexplained positive is followed up rather than dismissed.

Can you have lupus with a negative anti-dsDNA?

Yes. Only 50 to 70 percent of people with lupus are anti-dsDNA positive at diagnosis and about 30 percent never are. Lupus is diagnosed on a combination of symptoms, examination findings, a positive ANA and other antibodies such as anti-Smith, low complement, blood-count changes and kidney findings. Anti-dsDNA-negative lupus tends to have less kidney involvement and more skin and joint disease, but there are many exceptions.

What does anti-dsDNA positive with a negative ANA mean?

It is unusual, because DNA is a nuclear antigen and anti-dsDNA should light up the ANA screen. The most common explanation is a false positive ELISA, confirmed by a negative Crithidia test; less often the ANA was run on a solid-phase platform that missed it. Lupus with a persistently negative ANA is rare (under 5 percent). A repeat anti-dsDNA by a second method and an ANA by immunofluorescence usually resolve it.

Why does my anti-dsDNA go up and down?

The antibody is produced by immune cells whose activity rises and falls with the disease, and immune complexes are consumed during flares. In about half of patients the titer rises weeks to months before a flare, especially of nephritis, and falls with treatment; a doubling together with a drop in C3 and C4 is the pattern clinicians watch for. In the other half it moves independently of symptoms, so your doctor will decide how much weight to give it based on how it has behaved in you.

What is the difference between ANA and anti-dsDNA?

The ANA is a broad screen for antibodies against anything in the cell nucleus; it is positive in nearly all lupus but also in 10 to 15 percent of healthy people and many other conditions, so it cannot diagnose lupus. Anti-dsDNA is one specific antibody within that group; it is positive in only half to two thirds of lupus patients but rarely in anyone else, so it carries diagnostic weight. The ANA stays stable for years; anti-dsDNA often tracks disease activity.

Does anti-dsDNA matter in pregnancy?

Yes, as a marker of activity. Women who conceive with high anti-dsDNA, low complement and active disease have higher rates of flare, preeclampsia, preterm birth and fetal loss, which is why the usual advice is 6 months of quiet disease before trying. During pregnancy anti-dsDNA and complement are checked each trimester, and a rise with falling complement, protein in the urine or rising blood pressure distinguishes a lupus flare from preeclampsia, which can look similar.

References

ANA (antinuclear antibody) test. MedlinePlus, US National Library of Medicine (2023)View source
Aringer M, Costenbader K, Daikh D, et al.. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis & Rheumatology (2019)
Pisetsky DS. Anti-DNA antibodies — quintessential biomarkers of SLE. Nature Reviews Rheumatology (2016)
Kavanaugh AF, Solomon DH; American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis & Rheumatism (Arthritis Care & Research) (2002)
Arbuckle MR, McClain MT, Rubertone MV, et al.. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. New England Journal of Medicine (2003)
Isenberg DA, Manson JJ, Ehrenstein MR, Rahman A. Fifty years of anti-ds DNA antibodies: are we approaching journey's end?. Rheumatology (Oxford) (2007)
Fanouriakis A, Kostopoulou M, Andersen J, et al.. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Annals of the Rheumatic Diseases (2024)
Abou-Raya A, Abou-Raya S, Helmii M. The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial. Journal of Rheumatology (2013)
Freemer MM, King TE Jr, Criswell LA. Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Annals of the Rheumatic Diseases (2006)
Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab. Arthritis & Rheumatism (2000)
Lupus: diagnosis and treatment. Mayo Clinic (2022)
Systemic lupus erythematosus (SLE). Merck Manual Professional Version (2024)

Related markers

Related conditions

Evidence guides

Worried about your number?

Ask AskMN what your Anti-dsDNA result could mean in the context of your other results, symptoms and medications. Free, unlimited, no account needed.

Ask about my Anti-dsDNA

This page is educational and is not medical advice or a diagnosis. Lab results have to be interpreted together with your history, symptoms and other results by a clinician who knows you. Do not start or stop a supplement to change a lab value before the cause is known.